ARS Pharmaceuticals officer proposes $426K share sale
The notice reports 99,447,343 common shares outstanding in its securities information.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ARS Pharmaceuticals, Inc. (SPRY) officer Eric Karas gave notice of a proposed sale of 100,000 common shares, with an approximate sale date of October 1, 2026. Morgan Stanley Smith Barney LLC is named as broker; the stated aggregate market value is $426,096.77. The notice also lists prior three-month sales of 100,000 shares for $431,560.00 on September 30, 2026, and 14,064 shares for $69,761.66 on September 11, 2026. It lists 100,000 shares acquired by stock option exercise from the issuer for cash on October 1, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise technical
Securities Sold During The Past 3 Months regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What SPRY sales did Eric Karas report in the prior three months?
AI-generated analysis. How Rhea-AI works. Not financial advice.